Антифосфолипидный синдром - часть 25

105

коэффективной жидкостной хроматограф
фии. Биомедицинская химия, 2003; 6 с.

94. Shin YJ, Min SY, Cho ML, et al.

Enhanced nitric oxide production in endothelial
cells by antiphospholipid antibodies. ACR/ARHP
Annual Acientific Meeting, 2003, October 24—
28; 320 (abst).

95. Emmi L, Bergamini C, Spinelli A, Liotta F,

Marchione T, Caldini A, Fanelli A, DeCristo
faro MT, DalPozzo G. Possible pathogenetic role
of activated platelets in the primary antiphospho
lipid syndrome involving the central nervous sys
tem. Ann N Y Acad Sci 1997; 823: 188—200.

96. Campbell AL, Pierangeli SS, Wellhausen S,

Harris EN. Comparison of the effects of anticar
diolipin antibodies from patients with the
antiphospholipid syndrome and with syphilis on
platelet activation and aggregation. Thromb
Haemost 1995; 73: 529—534.

97. Nojima J, Suehisa E, Kuratsune H, Machii

T, Koike T, Kitani T, Kanakura Y, Amino N.
Platelet activation induced by combined effects of
anticardiolipin and lupus anticoagulant IgG anti
bodies in patients with systemic lupus erythemato
suspossible association with thrombotic and
thrombocytopenic complications. Thromb Hae
most 1999; 81: 436—441.

98. Wiener MH, Burke M, Fried M, Yust I.

Thromboagglutination by anticardiolipin anti
body complex in the antiphospholipid syndrome. a
possible mechanism of immunemediated throm
bosis. Thromb Res 2001; 103: 193—199.

99. Ferro D, Basili S, Roccaforte S, et al. Deter

minants of enhanced thromboxane biosynthesis in
patients with systemic lupus erythematosus,
Arthritis Rheum 1999; 42: 2689—2697. 

100. Reverter JC, Tassies D. Mechanisms of

thrombosis in the antiphospholipid syndrome:
binding to platelets. In Hughes Syndrome,
Antiphospholipid Syndrome. Edited by Khamash
ta MA. London: Springer—Verlag; 2000: 290—
298.

101. Joseph JE, Harrison P, Mackie IJ, et al.

Platelet activation markers and the primary
antiphospholipid syndrome (PAPS). Lupus 1998;
7 (Suppl 2): S48— S51. 

102. Reverter JC, Tassies D, Font J, et al.: Ef

fects of human monoclonal anticardiolipin anti
bodies on platelet function and on tissue factor

expression on monocytes. Arthritis Rheum 1998;
41: 1420—1427. 

103. Lackner KJ, von Landenberg C, Barlage

S, et al. Analysis of prothrombotic effects of two
human monoclonal IgG antiphospholipid anti
bodies of apparently similar specificity. Thromb
Haemost 2000; 83: 583— 588. 

104. Robbins DL, Leung S, MillerBlair DJ, et

al. Effect of anticardiolipin/beta2glycoprotein I
complexes on production of thromboxane A2 by
platelets from patients with the antiphospholipid
syndrome. J Rheumatol 1998; 25: 51—56.

105. George J, Gilburd B, Langevitz P, et al.

Beta 2 glycoprotein I containing immunecom
plexes in lupus patients: association with throm
bocytopenia and lipoprotein (a) levels. Lupus
1999; 8: 116—120. 

106. VegaOstertag M, Harris EN, Pierangeli

SS, et al. Phosphorilation of P38MAPK is invol
ved in antiphospholipid antibody mediated
platelet activation. ACR/ARHP Annual Acientific
Meeting, October, 2003; 24—28; 318 (abst).

107. Rock G, Chauhan K, Jamieson GA, et al.

AntiCD36 antibodies in patients with lupus anti
coagulant and thrombotic complications. Br J
Haematol 1994; 88: 878—880.

108. Pelegri Y, Cerrato G, Martinuzzo LO, et

al. Link between antiCD36 antibodies and
thrombosis in the antiphosphilipid syndrome. Clin
Exp Rheumatol 2003; 21: 221—224.

109. Daviet L, McGregor JL. Vascular biology

of CD36: roles of this new adhesion molecule
fanily in different disease states. Thromb Haemost
1997; 78: 65—69.

110. Stone S, Khamashta MA, Poston L. Pla

centation, antiphospholipid syndrome and preg
nancy outcome. Lupus 2001; 10: 67—74. 

111. Sthoeger ZM, Mozes E, Tartakovsky B.

Anticardiolipin antibodies induce pregnancy
failure by impairing embryonic implantation.
Proc Natl Acad Sci  USA 1993; 90: 6464—6467.

112. Rand JH, Wu XX, Andree HAM, et al.

Pregnancy loss in the antiphospholipidantibody
syndrome  a possible thrombogenic mechanism.
New Engl J Med 1997; 337:154—160.

113. McCrae KR, DeMichele AM, Pandhi P, et

al. Detection of antitrophoblast antibodies in the
sera of patients with anticardiolipin antibodies
and fetal loss. Blood 1993; 82: 2730—2741.

ГЛАВА 5. Патогенетические механизмы антифосфолипидного синдрома

Насонов Е.Л. Антифосфолипидный синдром

106

114. Peacemn AM, Rehnberg KA. The effect of

immunoglobulin G fraction from patients with
lupus anticoagulant on placental prostacyclin and
thromboxane production. Am J Obstet Gynecol
1995; 199: 1403—1406.

115. Donohoe S, Kingdom JCP, Mackie IJ:

Affinity purified human antiphospholipid anti
bodies bind normal term placenta. Lupus 1999; 8:
525—531.

116. Rote NS, Vogt E, DeVere G, et al. The role

of placental trophoblast in the pathophysiology of
the antiphospholipid antibody syndrome. Am J
Reprod Immunol 1998, 39: 125—136. 

117. Chamley LW, Duncalf AM, Mitchell MD,

et al. Action of anticardiolipin and antibodies to
beta 2 glycoprotein I on trophoblast proliferation
as a mechanism for fetal death. Lancet 1998;
352: 1037—1038. 

118. Di Simone N, Meroni PL, Del Papa N, et

al. Antiphospholipid antibodies affect trophoblast
gonadotrophin secretion and invasiveness by
binding directly and through adhered beta 2 gly
coprotein I. Arthritis Rheum 2000; 43: 140—153.

119. Shurtz SR, et al. In vitro effects of anticar

diolipin autoantibodies upon total and pulsatile
placental hCG secretion during early pregnancy.
Am J Reptoduct Immunol 1993; 29: 206—210.

120. Salmon JE, Girardi G, Holers VM.

Complement activation as a mediator of antiphos
pholipid antibody induced pregnancy loss and
thrombosis. Ann Rheum Dis 2002; 61: (Suppl II):
ii46—ii50.

121. Atkinson JP. Complement system on the

attack in autoimmunity. J Clin Invest 2003; 112:
1639—1641.

122. Girardi G, Berman J, Redecha P, et al.

Complement C5a receptors and neutrophil medi
ated fetal injury in the antiphospholipid syn
drome. J Clin Invest 2003; 112: 1644—1654.

123. Berman J, Girardi G, Salmon JE, et al.

Tumor necrosis factor

α is an important effector

in antiphospholipidinduced pregnancy loss in
mice. ACR/ARHP Annual Acientific Meeting,
October, 2003, 24—28; 1115 (abst). 

124. Sun KH, Liu WT, Tsai CY, Liao TS, Lin

WM, Yu CL. Inhibition of astrocyte proliferation
and binding to brain tissue of anticardiolipin anti
bodies purified from lupus serum. Ann Rheum Dis
1992; 51: 707—12.

125. Khalili A, Cooper RC. A study of immune

responses to myelin and cardiolipin in  patients
with systemic lupus erythematosus (SLE). Clin
Exp Immunol 1991; 85: 365—72.

126. Liou HH, Wang CR, Chou HC et al.

Anticardiolipin antisera from lupus patients  with
seizures reduce a GABA receptor—mediated chlo
ride current in snail neurons. Life Sci 1994; 54:
1119—25.

127. Kent M, Alvarez F, Vogt E, Fyffe R, Ng

AK, Rote N. Monoclonal antiphosphatidylserine
antibodies react directly with feline and murine
central nervous system. J Rheumatol 1997; 24:
1725—33.

128. Kent MN, Alvarez FJ, Ng AK, Rote NS.

Ultrastructural localization of monoclonal
antiphospholipid antibody binding to rat brain.
Exp Neurol 2000; 163: 173—9.

129. D`Cruz D, Hughes G. Antiendothelial cell

antibodies, antiphospholipid antibodies and vas
cular disease. Vasculitis Science and practice. B
Ansell, P Bacon, J Lie, H Yazici (eds). Chapmam
& Hall Medical 1996; 65—82.

130. Насонов ЕЛ, Баранов АА, Шилкина

НП. Васкулиты и васкулопатии. Яро
славль: Издательство "Верхняя Волга",
1999; 613 с.

131. Praprotnic S, Blank M, Meroni PL, et al.

Classification of antiendothelial cell antibodies
into antibodies against microvascular and
macrovascular endothelial cells. Arthritis Rheum
2001; 44: 1483—1494.

132. D`Cruz D, Houssiau FA., Ramirez G, et al.

Antibodies to endothelial cells in systemic lupus
erythematosus: a potential marker for nephritis
and vasculitis. Clin Exp Immunol 1991; 85:
254—261.

133. Navarro M, Cervera R, Font J, et al. Anti

endothelial antibodies in systemic autoimmune
diseases: prevalence and clinical significance.
Lupus 1997; 6: 521—526.

134. NylanderLundqvist E, Back O, Nillsson

TK, RantapaaDahlqvist S. Prevalence of anti
endothelial antibodies in patients with autoimmune
disease. Clin Rheumatol 1992; 11: 248—263.

135. Van der Zee JM, Siegert CE, de Vreede

TA, et al. Characterisation of antiendothelial
cell antibodies in systemic lupus erythematosus
(SLE). Clin Exp Immunol 1991; 84:238—244.

107

136. Perry GJ, Elston T, Khouri NA, et al. Anti

endothelial cell antibodies in lupus: correlation
with renal injury anf circulating marker of
endothelial damage. Q J Med 1993; 86: 727—734.

137. Chan TM, Yu PM, Tsang LC, Cheng IKP.

Endothelial cell binding by human polyclonal
antiDNA antibodies: relationship to disease
activity and endothelial function alteration. Clin
Exp Immunol 1995; 100: 506—513.

138. Del Papa N, Guidali L, Spatola L, et al.

Relationship between antiphospholipid and
antiendothelial vell antibodies III: beta 2 glyco
protein I mediates the antibody binding to
endothelial membranes and induce the expression
of adhesion molecules. Clin Exp Rheumatol 1995;
13: 179—185.

139. Garvalho D, Savage COS, Isenberg D,

Pearson JD. IgG antiendothelial cell autoanti
bodies from patients with systemic lupus erythe
matosus or systemic vasculitis stimulate the
release of two endothelial cellderived mediators,
which enhance adhesion molecule expression and
leukocyte adhesion in an autocrine manner.
Arthritis Rheum 1999; 42: 631—640.

140. McGrae KR, de Michele A, Samuels P, et

al. Detection of endothelial cell reactive
immunoglobulin in patients with antiphospholipid
antibodies. Br J Heamatol 1991; 79: 595—605.

141. Del Papa N, Raschini E, Moroni G, et al.

Antiendothelial cell IgG fraction from sysyemic
lupus erythematosus patients bind to human
endothelial cell and induce a proadhesive and
proinflammatory phenotype in vitro. Lupus
1999; 8: 423—429.

142. Hill MB, Philips JL, Hughes P, Greaves

M. Antiendothelial cell antibodies in primary
antiphospholipid syndrome and SLE: pattern of
reactivity with membrane antigens on microvas
cular and umbilical venous cell membranes. Br J
Haematol. 1998; 103: 416—421.

143. Насонов ЕЛ, Алекберова ЗС, Саложин

КВ, Клюквина НГ, Александрова ЕН, Баранов
АА, Ле Тонкез М, Юну П. Антиэндотелиаль
ные антитела при системной красной вол
чанке у мужчин: связь с поражением почек и
антифосфолипидным синдромом. Терапевт.
архив, 1996; 6: 46—49.

144. Калашникова ЛА, Саложин КВ, Насо

нов ЕЛ, Кошелева НМ, Решетняк ТМ, Сто

янович ЛЗ. Антитела к эндотелию при синд
роме Снеддона. Терапевт. архив, 1996; 1:
54—57.

145. Frances G, Le Tonqueze M, Salozhin K,

Kalasdhnikova L, Piette JC, Nasonov EL,
Godeau P, Youinou P. Prevalence of anti
endothelial cell antibodies in patients with
Sneddon`s syndrome. J Amer Acad Dermatol
1995; 33: 64—68.

146. Насонов ЕЛ, Саложин КВ, Фомичева

ОА, Клюквина НГ, Карпов ЮА, Вильчинская
МЮ, Александрова ЕН, Алекберова ЗС, Ба
ранов АА, Сергакова ЛМ. Антиэндотелиаль
ные антитела и поражение клапанов сердца
при антифосфолипидном синдроме: анализ
патогенетических механизмов. Клин. меди
цина, 1997; 2: 17—21.

147. Cervera R, Khamashta MA, Font J, et al.

Antiendothelial cell antibodies in patients with the
antiphospholipid syndrome. Autoimmunity 1991;
11: 1—6.

148. Walker TS, Triplett DA, Javed N, et al.

Evaluation of lupus anticoagulants: antiphospho
lipid antibodies, endothelium associated im
munoglobulin in patients with antiphospholipid
antibodies Thromb Res 1988; 51: 595—605.

149. GarciaTorress R, Amogo MC, de la

Rossa A, Reyes PA. Valvular heart disease in
primary antiphospholipid syndrome (PAPS):
clinical and morphological findings. Lupus
1996; 5: 56—61.

150. Guilly MN, Danon F, Brouet JC, et al.

Autoantibodies to nuclear lamin B in patients with
thrombocytopenia. Eur J Cell Biol 1987; 43:
266—272.

151. Lassoued K, Guilly MN, Danon F, et al.

Antinuclear autoantibodies specific for lamins:
characterization and clinical significance. Ann
Intern Med 1988; 108: 829—833.

152. Senecal JL, Rauch J, Grodzicky T, et al.

Strong association of autoantibodies to human
nuclear lamin B1 with lupus anticoagulant anti
bodies in systemic lupus erythematosus Arthritis
Rheum 1999; 42: 1347—1353. 

153. Клюквина НГ, Баранов ЕЛ, Александ

рова ЕН, Насонов ЕЛ. Среактивный белок
при системной красной волчанке у мужчин:
связь с тромботическими осложнениями.
Клин. медицина, 1997; 8: 24—26.

ГЛАВА 5. Патогенетические механизмы антифосфолипидного синдрома

Насонов Е.Л. Антифосфолипидный синдром

108

154. Papo T, Piette JC, Legao E, et al. T lym

phocytes subsets in primary antiphospholipid syn
drome. J Rheumatol 1994; 21: 2242—2245.

155. Arnett FC, Olsen ML, Anderson KL,

Reveille JD. Molecular analysis of major histo
compatibility complex alleles associated with the
lupus anticoagulant. J Clin Invest 191; 87:
1490—1495.

156. Loizou S, Cofiner C., Weetman AP,

Walport MJ. Immunoglobulin class and IgG sub
class distribution of anticardiolipin antibodies in
patients with systemic lupus erythematosus and
associated disorders. Clin Exp Immunol 1992;
90: 434—439.

157. Kita Y, Sumida T, Iwamoto I, et al. V gene

analysis of anticardiolipin antibodies from
(NZWXBXSB) F1 mice. Immunology 1994; 82:
494—501.

158. Blank M, Krause I., Lanir N, et al.

Transfer of experimental antiphоspholipid syn
drome by bone marrow cell transplantation: the
importance of the T cell. Arthritis Rheum 1995;
38: 115—122.

159. Visvanathan S, McNeil HP. Cellular

immunity to 

β

2

glycoprotein I in patients with

antiphospholipid syndrome. J Immunol 1999;
162: 6919—6925.

160. Hattori N, Kuwana M, Kabukai J, et al. T

cell that are autoreactive to 

β

2

glycoprotein I in

patients with antiphospholipid syndrome and
healthy individuals. Arthritis Rheum 2000; 43:
65—75.

161. Davies ML, Young SP, Welsh K, et al.

Immune responses to native 

β2glycoproteim I in

patients with systemic lupus erythematosus and
the antiphospholipid syndrome. Rheumatology
2002; 41: 395—400.

162. Del Prete G, De Carli M, Lammel RM, et

al. Th1 and Th2 Thelper cells exert opposite reg
ulatory effects on procoagulant activity and tissue
factor production by monocytes. Blood 1995; 250
(abst).

163. Wegmann TG, Lin H, Guilbert L, Mos

mann TR. Bidirectional cytokine interactions in
the maternalfetal relationship: is successful preg
nancy a TH2 phenomenon? Immunol Today
1993; 13: 353.

164. Raghupathy R. Th1type immunity is

incompatible with successful pregnancy. Immunol
Today 1997; 18: 478.